Possibilities for diagnostics of non-alcoholic fatty liver disease in patients with metabolically associated comorbid pathology


DOI: https://dx.doi.org/10.18565/therapy.2023.7.22-31

Aryamkina O.L., Dobrynina I.Yu., Biek A.Yu., Saitov A.R., Tarasova L.V., Zapevalov A.V., Grishmanovsky P.V., Grishmanovskaya O.N.

1) Surgut State University; 2) Surgut Regional Clinical Hospital; 3) I.N. Ulyanov Chuvash State University, Cheboksary
Abstract. Article presents the data on the possibility of diagnosing non-alcoholic fatty liver disease (NAFLD) and stratification of its stages in patients with metabolic syndrome based on the developed computer program – non-invasive calculator «Diagnostics of non-alcoholic fatty liver disease», posted on the website of Surgut State University. The background causes for its creation were an increase in the number of NAFLD patients, which occurs in the vast majority of cases with few symptoms, epidemics of obesity, type 2 diabetes mellitus, which form the basis of the metabolic syndrome, an unfavorable epidemiological situation in cardiovascular diseases, a proven interdependence between fibrotic liver reorganization and cardiovascular events. Staging of the course of NAFLD from hepatic steatosis to non-alcoholic steatohepatitis and cirrhosis during its natural clinical course, necessary polypharmacy in the metabolic syndrome require an estimation of the rate of that liver disease progression for timely accepting the decisions on patients’ management.
The aim: to show the possibility of using a non-invasive calculator for the early diagnosis of NAFLD and its stages in patients with comorbidity in case of metabolic syndrome.
Material and methods. A complex study was carried out for the presence of NAFLD in metabolic syndrome in two groups of 2030 patients, 96 of which, along with other things, had hyperammonemia. Results and conclusion. Suggested methodic – the use of the original non-invasive calculator
«Diagnosis of non-alcoholic fatty liver disease» – allows, based on a complex of 9 clinical and laboratory data (presence of obesity, arterial hypertension, hyperglycemia, hepatomegaly, ALT, AST values, results of the number connection test, NAFLD Fibrosis Score, and also the level of ammonia in the blood as one of the criteria for hepatocellular insufficiency) to improve the verification of this oligosymptomatic disease, as well as the stratification of its stages in patients.
Keywords: non-alcoholic fatty liver disease, metabolic syndrome
Read entire article

Literature

1. Драпкина О.М., Буеверов А.О. Неалкогольная жировая болезнь печени как мультидисциплинарная патология. Серия «Библиотека терапевта». М.: Видокс, 2019; 104 с. [Drapkina O.M., Bueverov A.O. Non-alcoholic fatty liver disease as a multidisciplinary pathology. Series «Library for therapists». Moscow: Vidoks. 2019; 104 pp. (In Russ.)]. ISBN: 978-5-9500825-6-6. EDN: TQXHAD.


2. Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019; (10): 57–65. [Livzan M.A., Gaus O.V., Nikolaev N.A., Krolevetz T.S. NAFLD: comorbidity and associated diseases. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2019; (10): 57–65 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-170-10-57-65. EDN: DACLIE.


3. Токтогулова Н.А., Сыдыкбекова А.А., Сатаров У.А. Распространенность ультразвуковых признаков жирового гепатоза и сочетанных патологий у стационарных больных в Кыргызстане. Здравоохранение Кыргызстана. 2022; (4): 68–74. [Toktogulova N.A., Sydykbekova A.A., Satarov U.A. The prevalence of ultrasound signs of fatty hepatosis and comor bidities in hospital patients in Kyrgyzstan. Zdravookhraneniye Kyrgyzstana = Healthcare of Kyrgyzstan. 2022; (4): 68–74 (In Russ.)]. https://dx.doi.org/10.51350/zdravkg2022.4.10.9.68. EDN: XXXDZA.


4. Garteiser P., Castera L., Coupaye M. et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. JHEP Rep. 2021; 3(6): 100381. https://dx.doi.org/10.1016/j.jhepr.2021.100381.


5. Popa A., Sirli R., Popescu A. et al. Ultrasound-based quantification of fibrosis and steatosis with a new software considering transient elastography as reference in patients with chronic liver diseases. Ultrasound Med Biol. 2021; 47(7): 1692–703. https://dx.doi.org/10.1016/j.ultrasmedbio.2021.02.029.


6. Лазебник Л.Б., Радченко В.Г., Голованова Е.В. с соавт. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия). Экспериментальная и клиническая гастроэнтерология. 2017; (2): 22–37. [Lazebnik L.B., Radchenko V.G., Golovanova E.V. et al. Non-alcoholic fatty liver disease: clinic, diagnostics, treatment (Recommendations for therapists, 2nd edition). Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2017; (2): 22–37 (In Russ.)]. EDN: YHTWFH.


7. Лазебник Л.Б., Голованова Е.В., Туркина С.В. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; (1): 4–52. [Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (1): 4–52 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-185-1-4-52. EDN: KJLOJV.


8. Широкова Е.Н. Неалкогольная жировая болезнь печени и кардиоваскулярный риск (обзор литературы). Фарматека. 2017; (2): 24–29. [Shirokova E.N. Non-alcoholic fatty liver disease and cardiovascular risk (literature review). Farmateka. 2017; (2): 24–29 (In Russ.)]. EDN: YIBBTV.


9. Широкова Е.Н. Неалкогольная жировая болезнь печени, гиперлипидемия и сердечно-сосудистые риски. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2017; (2): 74–76. [Shirokova E.N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Gastroenterologiya. Prilozheniye k zhurnalu Consilium Medicum = Gastroenterology. Supplement to Consilium Medicum. 2017; (2): 74–76 (In Russ.)]. https://dx.doi.org/10.26442/2075-1753_19.8.2.74-76. EDN: ZTUTGP.


10. Цуканов В.В., Васютин А.В., Тонких Ю.Л. Новые аспекты неалкогольной жировой болезни печени. Доктор.Ру. 2021; 20(4): 33–39. [Tsukanov V.V., Vasyutin A.V., Tonkikh Yu.L. New aspects of non-alcoholic fatty liver disease. Doctor.Ru. 2021; 20(4): 33–39 (In Russ.)]. https://dx.doi.org/10.31550/1727-2378-2021-20-4-33-39. EDN: CFFIRM.


11. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non- alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. https://dx.doi.org/10.1016/j.jhep.2015.11.004.


12. World Health Organization. ICD-11 Implementation or Transition Guide. 2019. URL: https://icd.who.int/en/docs/ICD-11%20 Implementation%20or%20Transition%20Guide_v105.pdf (date of access – 01.09.2023).


13. Eslam M., Newsome P.N., Anstee Q.M. et al. A new definition for metabolic associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1): 202–9. https://dx.doi.org/10.1016/j.jhep.2020.03.039.


14. Eslam M., Sanyal A.J., George J.; International Consensus Panel. MAFLD: A consensus driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158(7): 1999–2014.e1. https://dx.doi.org/10.1053/j.gastro.2019.11.312.


15. Fouad Y., Waked I., Bollipo S. et al. What’s in a name? Renaming «NAFLD» to «MAFLD». Liver Int. 2020; 40(6): 1254–61. https://dx.doi.org/10.1111/liv.14478.


16. Shi Z., Tuomilehto J., Kronfeld-Schor N. et al. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med. 2021; 289(6): 851–60. https://dx.doi.org/10.1111/joim.13204.


17. Le M.H., Le D.M., Baez T.C. et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023; 79(2): 287–95. https://dx.doi.org/10.1016/j.jhep.2023.03.040.


18. Токтогулова Н.А., Султаналиева Р.Б., Тухватшин Р.Р., Калиев Т.К. Липидный обмен при неалкогольной жировой болезни печени у больных с различной массой тела в условиях среднегорья. Терапевтический архив. 2022; 94(12): 1361–1366. [Toktogulova N.A., Sultanalieva R.B., Tukhvatshin R.R., Kaliev T.K. Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(12): 1361–1366 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.12.201998. EDN: RFLQWI.


19. Дедов И.И., Мельниченко Г.А., Шестакова М.В. с соавт. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018; 15(1): 53–70. [Dedov I.I., Melnichenko G.A., Shestakova M.V. et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (morbid obesity treatment in adults). Ozhireniye i metabolizm = Obesity and Metabolism. 2018; 15(1): 53–70 (In Russ.)]. https://dx.doi.org/10.14341/omet2018153-70. EDN: OUJNNF.


20. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. с соавт. Ожирение. Consilium Medicum. 2021; 23(4): 311–325. [Dedov I.I., Mokrysheva N.G., Melnichenko G.A. et al. Obesity. Consilium Medicum. 2021; 23(4): 311–325 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2021.4.200832. EDN: GYUVLJ.


21. Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. с соавт. Метаболический синдром: история развития, основные критерии диагностики. Рациональная фармакотерапия в кардиологии. 2018; 14(5): 757–764. [Belenkov Yu.N., Privalova E.V., Kaplunova V.Yu. et al. Metabolic syndrome: history of development, main diagnostic criteria. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2018; 14(5): 757–764 (In Russ.)]. https://dx.doi.org/10.20996/1819-6446-2018-14-5-757-764. EDN: YPESEX.


22. Пальгова Л.К. Группы риска по развитию неалкогольной жировой болезни печени: кому и как проводить скрининг. Эффективная фармакотерапия. 2017; (16): 26–32. [Palgova L.K. Risk groups for the development of non-alcoholic fatty liver disease: who and how to screen. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2017; (16): 26–32 (In Russ.)]. EDN: YMHFND.


23. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18(1): 5–66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbid pathology in clinical practice. Algorithms for diagnosis and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019; 18(1): 5–66 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2019-1-5-66. EDN: YXKKAP.


24. Оганов Р.Г., Денисов И.Н., Симаненков В.И. с соавт. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017; 16(6): 5–56. [Oganov R.G., Denisov I.N., Simanenkov V.I. et al. Comorbidities in practice. Clinical guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2017; 16(6): 5–56 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2017-6-5-56. EDN: ZVZZGR.


25. Верижникова Л.Н., Арямкина О.Л., Терентьева Н.Н. Соматическая патология у жителей Ханты-Мансийского автономного округа – Югры. Бюллетень сибирской медицины. 2020; 19(2): 13–19. [Verizhnikova L.N., Aryamkina O.L., Terentyeva N.N. Somatic pathology among residents of the Khanty-Mansiysk Autonomous Okrug – Yugra. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2020; 19(2): 13–19 (In Russ.)]. https://dx.doi.org/10.20538/1682-0363-2020-2-13-19. EDN: ZRLKZC.


26. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26(2): 24–42. [Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26(2): 24–42 (In Russ.)]. EDN: YIYGHP.


27. Андреев Д.Н., Маев И.В., Дичева Д.Т., Кузнецова Е.И. Диагностика и лечение неалкогольной жировой болезни печени: обзор Европейских рекомендаций 2016 года. Consilium medicum. 2017; 19(8): 8–13. [Andreev D.N., Maev I.V., Dicheva D.T., Kuznetsova E.I. Diagnosis and treatment of non-alcoholic fatty liver disease: a review of the 2016 European guidelines. Consilium medicum. 2017; 19(8): 8–13 (In Russ.)]. EDN: ZRSTGT.


28. Бабенко А.Ю., Лаевская М.Ю. Неалкогольная жировая болезнь печени – взаимосвязи с метаболическим синдромом. РМЖ. 2018; 26(1–1): 34–40. [Babenko A.Yu., Laevskaya M.Yu. Non-alcoholic fatty liver disease – relationship with metabolic syndrome. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2018; 26(1–1): 34–40 (In Russ.)]. EDN: YAIZRJ.


29. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL–ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63(1): 237–64. https://dx.doi.org/10.1016/j.jhep.2015.04.006.


30. Маев И.В., Андреев Д.Н., Дичева Д.Т., Кузнецова Е.И. Неалкогольная жировая болезнь печени. М.: Прима Принт. 2017; 64 с. [Maev I.V., Andreev D.N., Dicheva D.T., Kuznetsova E.I. Non-alcoholic fatty liver disease. Moscow: Prima Print. 2017; 64 p. (In Russ.)].


31. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. с соавт. Неалкогольная жировая болезнь печени с позиций современной медицины. С положениями консолидированных российских клинических рекомендаций (2022 г.). 2-е издание. Серия «Клиническая гепатология». М.: Прима Принт. 2020; 68 с. [Maev I.V., Andreev D.N., Kucheryavy Yu.A. et al. Non-alcoholic fatty liver disease from the standpoint of modern medicine. With the provisions of the consolidated Russian clinical guidelines (2022). 2nd edition. Series «Clinical hepatology». Moscow: Prima Print. 2020; 68 pp. (In Russ.)]. ISBN: 978-5-6042241-5-1. EDN: CWZQFI.


32. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Печень и билиарный тракт при метаболическом синдроме. Пособие для врачей. Серия «Клиническая гепатология». М.: Прима Принт. 2020; 52 с. [Maev I.V., Kucheryavy Yu.A., Andreev D.N. Liver and biliary tract in metabolic syndrome. Manual for doctors. Series «Clinical hepatology». Moscow: Prima Print. 2020; 52 pp. (In Russ.)]. ISBN: 978-5-6044391-1-1. EDN: RECXYQ.


33. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Российский консенсус «Гипераммониемии у взрослых». Экспериментальная и клиническая гастроэнтерология. 2019; (12): 4–23. [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Russian consensus «Hyperammonemia in adults». Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2019; (12): 4–23 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-172-12-4-23. EDN: CBRGXX.


34. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Российский консенсус «Гипераммониемии у взрослых» (версия 2021). Экспериментальная и клиническая гастроэнтерология. 2021; (3): 97–118. [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Russian consensus «Hyperammonemia in adults» (version 2021). Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (3): 97–118 (In Russ.)]. https://dx.doi.org/10.31146/1682- 8658-ecg-187-3-97-118. EDN: IXZDGZ.


35. Консенсус экспертов по междисциплинарному подходу к ведению, диагностике и лечению больных с метаболическим синдромом. Кардиоваскулярная терапия и профилактика. 2013; 12(6): 41–82. [Expert consensus on an interdisciplinary approach to the management, diagnosis and treatment of patients with metabolic syndrome. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2013; 12(6): 41–82 (In Russ.)]. EDN: RSYQYP.


36. Биек А.Ю., Саитов А.Р., Бессонова А.Р. с соавт. Коморбидность при метаболическом синдроме у жителей региона, приравненного к Крайнему Северу. Вестник СурГУ. Медицина. 2020; (2): 80–86. [Biek A.Yu., Saitov A.R., Bessonova A.R. et al. Comorbidity in metabolic syndrome among residents of a region equivalent to the Far North. Vestnik SurGU. Meditsina = Bulletin of the Surgust State University. Medicine. 2020; (2): 80–86 (In Russ.)]. https://dx.doi.org/10.34822/2304-9448-2020-2-80-86. EDN: THKKLI.


37. Лазебник Л. Б., Туркина С. В. НАЖБП-ассоциированная коморбидность. Экспериментальная и клиническая гастроэнтерология. 2021; (10); 5–13. [Lazebnik L.B., Turkina S.V. NAFLD associated comorbidity. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (10); 5–13 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-194-10-5-13. EDN: VLADFJ.


38. Маршалко Д.В., Пчелин И.Ю., Шишкин А.Н. Неалкогольная жировая болезнь печени: коморбидность, клиническое значение и методы диагностики фиброза печени. Juvenis Scientia. 2018; (2): 14–17 (In Russ.). [Marshalko D.V., Pchelin I.Yu., Shishkin A.N. Non-alcoholic fatty liver disease: Comorbidity, clinical significance and diagnostic methods for liver fibrosis. Juvenis Scientia. 2018; (2): 14–17 (In Russ.)]. EDN: YSMDUQ.


About the Autors

Olga L. Aryamkina, MD, professor, head of the Department of internal medicine, Surgut State University. Address: 628403, Surgut, 1 Lenina Avenue. E-mail: arjam56@mail.ru. ORCID: https://orcid.org/0000-0002-0149-6103
Irina Yu. Dobrynina, MD, professor, professor of the Department of internal medicine, Surgut State University, endocrinologist at Surgut Regional Clinical Hospital. Address: 628403, Surgut, 1 Lenina Avenue.
E-mail: diu_surgut@mail.ru. ORCID: https://orcid.org/0000-0002-4849-0200
Alfred Yu. Biek, graduate of the doctorate of the Department of internal medicine, Surgut State University, general practitioner at Surgut Regional Clinical Hospital. Address: 628408, Surgut, 14 Energetikov Str.
E-mail: alfred_1991@mail.ru. ORCID: https://orcid.org/0000-0002-5786-8455
Aziz R. Saitov, graduate of the doctorate of the Department of internal medicine, Surgut State University, general practitioner at Surgut Regional Clinical Hospital. Address: 628408, Surgut, 14 Energetikov Str.
E-mail: noghay_05@bk.ru. ORCID: https://orcid.org/0000-0003-2966-8277
Larisa V. Tarasova, MD, associate professor, professor of the Department of internal medicine, Surgut State University, head of the Department of hospital therapy, I.N. Ulyanov Chuvash State University. Address: 428015, Cheboksary, 45 Moskovsky Avenue. E-mail: tlarisagast18@mail.ru. ORCID: https://orcid.org/0000-0003-1496-0689
Andrey V. Zapevalov, PhD in Technical Sciences, associate professor, head of the Department of automation and computer systems, Surgut State University. Address: 628403, Surgut, 1 Lenina Avenue. E-mail: zapevalov_av@surgu.ru. ORCID: https://orcid.org/0009-0007-1313-8913
Pavel V. Grishmanovsky, PhD in Technical Sciences, associate professor of the Department of automation and computer systems, Surgut State University. Address: 628403, Surgut, 1 Lenina Avenue. E-mail: grishmanovskiy_pv@surgu.ru. ORCID: https://orcid.org/0009-0007-2247-4409
Olga N. Grishmanovskaya, postgraduate student, senior lecturer at the Department of automation and computer systems, Surgut State University. Address: 628403, Surgut, 1 Lenina Avenue. E-mail: grishmanovskaya_on@surgu.ru. ORCID: https://orcid.org/0009-0003-3382-8920


Similar Articles

Back to Content

Бионика Медиа